Literature DB >> 10639641

Adjunctive Antiplatelet Therapy in Acute Myocardial Infarction: The Road to Improved Infarct-Related Artery Patency.

.   

Abstract

A direct relationship exists between infarct artery patency and survival in patients with acute myocardial infarction. Currently available thrombolytic regimens produce 90 minute patency rates on the order of 80%. Preliminary trials suggest that adjunctive anti-platelet therapy with glycoprotein IIb/IIIa inhibitors, in conjunction with thrombolytic therapy, may significantly improve 90 minute infarct related artery patency and thereby survival, in patients with acute myocardial infarction.

Entities:  

Year:  1997        PMID： 10639641     DOI： 10.1023/a:1008845315933

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  11 in total

Review 1.  The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

Authors:  V Fuster; L Badimon; J J Badimon; J H Chesebro
Journal:  N Engl J Med       Date:  1992-01-23       Impact factor: 91.245

Review 2.  Antiplatelet agents in the prevention and therapy of thrombosis.

Authors:  B S Coller
Journal:  Annu Rev Med       Date:  1992       Impact factor: 13.739

3.  Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.

Authors:  E M Ohman; N S Kleiman; G Gacioch; S J Worley; F I Navetta; J D Talley; H V Anderson; S G Ellis; M D Cohen; D Spriggs; M Miller; D Kereiakes; S Yakubov; M M Kitt; K N Sigmon; R M Califf; M W Krucoff; E J Topol
Journal:  Circulation       Date:  1997-02-18       Impact factor: 29.690

4.  Randomized, Placebo-Controlled Study of Lamifiban with Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction: Rationale and Design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Study.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

5.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-02       Impact factor: 91.245

6.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

7.  Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.

Authors:  N S Kleiman; E M Ohman; R M Califf; B S George; D Kereiakes; F V Aguirre; H Weisman; T Schaible; E J Topol
Journal:  J Am Coll Cardiol       Date:  1993-08       Impact factor: 24.094

8.  Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.

Authors:  R J Simes; E J Topol; D R Holmes; H D White; W R Rutsch; A Vahanian; M L Simoons; D Morris; A Betriu; R M Califf
Journal:  Circulation       Date:  1995-04-01       Impact factor: 29.690

9.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-07       Impact factor: 91.245

10.  Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.